Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143489
Full metadata record
DC FieldValueLanguage
dc.creatorConceição, P
dc.creatorAbreu, C
dc.date.accessioned2022-08-29T14:34:56Z-
dc.date.available2022-08-29T14:34:56Z-
dc.date.issued2020
dc.identifier.issn0870-399X
dc.identifier.urihttps://hdl.handle.net/10216/143489-
dc.description.abstractIntroduction: Rabies is one of the oldest and deadliest infectious diseases known by human beings and is commonly transmitted by animal bites. Dogs have a major role in the transmission of the virus. Rabies has no approved curative therapy, and its prevention, even though it is highly effective, it is complex, expensive and challenging in terms of accessibility, particularly regarding immunoglobulin. This review aims to provide a practical approach to cost-effective prevention as well as the future perspectives regarding the development of an effective and secure cure. Material and Methods: This review article was based on a search in PubMed using the following MeSH terms: rabies, preexposure and postexposure prophylaxis, rabies immune globulin, treatment, Milwaukee Protocol. Results: Concerning rabies infection, it's important to apply the prevention protocols effectively as early as possible due the unpredictable time window between infection and the appearance of symptoms. The literature shows that is possible to reduce the vaccination dosage and maintain the efficiency of the immunization, and booster vaccination is only required in specific risk groups/populations. Discussion: The current philosophy of cost-effective prevention which consists of canine vaccination, restriction of vaccine overdosage used in humans and the appropriate use of rabies immunoglobulin - could make the prevention of the disease accessible for those countries that need it the most. There are several therapies in development but they're all in early stages of development. Conclusion: The development of new and more effective therapeutic and prophylactic approaches is a goal not yet achieved and relies on a better understanding of the disease pathophysiology.
dc.language.isopor
dc.publisherOrdem dos Médicos
dc.relation.ispartofActa Medica Portuguesa, vol.34(11), p. 767-773
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject Immunoglobulins
dc.subjectRabies Vaccines
dc.subjectRabies/immunology
dc.subjectRabies/prevention & control
dc.subjectRabies/therapy
dc.subject.meshAnimals
dc.subject.meshCost-Benefit Analysis
dc.subject.meshDogs
dc.subject.meshHumans
dc.subject.meshImmunologic Factors
dc.subject.meshRabies Vaccines
dc.subject.meshRabies / prevention & control
dc.subject.meshVaccination
dc.titleHuman rabies: Optimization of prevention and paths towards the cure
dc.typeArtigo em Revista Científica Nacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.20344/AMP.10657
dc.relation.publisherversionhttps://actamedicaportuguesa.com/revista/index.php/amp/article/view/10657
Appears in Collections:I3S - Artigo em Revista Científica Nacional

Files in This Item:
File Description SizeFormat 
10.20344-AMP.10657.pdf447.04 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons